Singular Genomics Systems, Inc. (OMIC)

Market Cap	30.70M
Revenue (ttm)	2.91M
Net Income (ttm)	-94.82M
Shares Out	74.09M
EPS (ttm)	-1.30
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	77,805
Open	0.400
Previous Close	0.400
Day's Range	0.400 - 0.428
52-Week Range	0.310 - 1.210
Beta	1.40
Analysts	Hold
Price Target	0.68 (+64.09%)
Earnings Date	May 7, 2024

About OMIC

Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and spatial multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: May 27, 2021
• Employees: 255
• Stock Exchange: NASDAQ
• Ticker Symbol: OMIC

Financial Performance

In 2023, OMIC's revenue was $2.91 million, an increase of 280.52% compared to the previous year's $765,000. Losses were -$94.82 million, 4.34% more than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for OMIC stock is "Hold." The 12-month stock price forecast is $0.68, which is an increase of 64.09% from the latest price.

Price Target

$0.68

(64.09% upside)

Analyst Consensus: Hold